Ponatinib and Blinatumomab for Patients with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia in Lymphoid Blast Phase: A Subgroup Analysis from a Phase II Study

作者
Walid Macaron,Hagop Kantarjian,Nicholas James Short,Nitin Jain,Xuelin Huang,Guillermo Montalban Bravo,Tapan Mahendra Kadia,Naval Guastad Daver,Kelly Sharon Chien,Yesid Alvarado,Guillermo Garcia‐Manero,Ghayas C. Issa,Fadi Haddad,Monica I. Kwari,Ricardo Delumpa,Ejiroghene Mayor,Wuliamatu Deen,Jennifer Thankachan,Christopher R. Loiselle,Juan Rivera
出处
期刊:Blood [Elsevier BV]
卷期号:140 (Supplement 1): 8973-8975 被引量:2
标识
DOI:10.1182/blood-2022-157323
摘要

Background: Ponatinib and blinatumomab are both highly effective in relapsed or refractory Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The combination of these two agents may lead to deep and durable responses without the need for chemotherapy. Methods: In this phase II study, adults with relapsed/refractory (R/R) Ph+ ALL or chronic myeloid leukemia in lymphoid blast phase (CML-LBP) were eligible. Results from patients (pts) with newly diagnosed Ph+ ALL are being reported separately. Pts were required to have a performance status of ≤2, total bilirubin ≤2x the upper limit of normal (ULN), and alanine aminotransferase and aspartate aminotransferase ≤3x the ULN. Pts with uncontrolled cardiovascular disease or clinically significant central nervous system (CNS) comorbidities (except for CNS leukemia) were excluded. Pts received up to 5 cycles of blinatumomab as a continuous infusion at standard doses. Ponatinib 30mg daily was given during cycle 1. Ponatinib was decreased to 15mg daily once a complete molecular response (CMR) was achieved. After completion of blinatumomab, ponatinib was continued for at least 5 years in responding pts. Twelve doses of prophylactic intrathecal chemotherapy with alternating cytarabine and methotrexate were administered. The primary endpoint was the overall response rate (defined as the composite of CR/CRi). Secondary endpoints included safety measures, complete molecular response (CMR) rate, event-free survival (EFS) and overall survival (OS). Results: Between February 2018 and June 2022, 20 patients were treated (14 R/R and 6 CML-LBP). Baseline characteristics are shown in Table 1. The median age of the R/R Ph+ ALL and CML-LBP cohorts were 38 years (range, 24-61) and 69 years (range, 29-82), respectively. BCR::ABL1 transcripts were p190 in 93% in the R/R cohort. 43% of pts in the R/R Ph+ ALL cohort were in salvage 2 or beyond. Among the CML-LBP pts, 3 were de novo and 3 were transformed from previously treated CML (1 of whom had received prior therapy for LBP). Among the 14 pts with R/R Ph+ ALL, 1 was in CR but still with detectable BCR::ABL1 at enrollment. 12 of the 13 evaluable pts (92%) achieved CR/CRi, with CR in 11 pts (85%). The one non-responding pt had received prior ponatinib-based therapy in an earlier salvage regimen. After one cycle, 11/14 (79%) achieved MMR and 10/14 pts (71%) achieved CMR. 12/14 (86%) achieved MMR and 11/14 pts (79%) achieved CMR at any time over the course of therapy. Among the 6 pts with CML-LBP, 5 (83%) achieved CR/CRi, and 1 achieved PR as best response. After one cycle, 1/6 pts (17%) achieved MMR and CMR. 3/6 (50%) achieved MMR and 2/6 (33%) achieved CMR at any time over the course of therapy. The median follow-up is 22 months (range, 6-51+ months) in the R/R cohort, and 25 months (range, 11-38+ months) in the CML-LBP cohort. Among the 14 pts in the R/R cohort, 1 did not respond, 6 proceeded to allogeneic stem cell transplant (ASCT) (1 of whom relapsed post-ASCT and died and 5 of whom are still alive without relapse), 4 did not undergo ASCT and subsequently relapsed after a median of 6.4 months (range, 2.7-8.1), 1 died in CR, and 2 are in ongoing response without ASCT. Of the 5 relapses, 2 were hematologic only, 2 were in the CNS with MRD positivity in the bone marrow, and 1 was CNS only. The estimated 2-year EFS and OS for the R/R cohort are 46% and 59%, respectively (Figure 1). Among the 5 pts in the CML-LBP cohort who achieved CR/CRi, 3 relapsed (1 of whom had an immunophenotypic switch to a myeloid blast phase CML with loss of CD19 expression) and 2 are in ongoing response without ASCT. The estimated 2-year EFS and OS for the CML-LBP cohort are 33% and 60%, respectively (Figure 1). Grade 3 adverse events observed on study were: febrile neutropenia, cytokine release syndrome, lipase increase, and alkaline phosphatase increase in 1 pt each. There were no grade 4-5 events. One pt discontinued ponatinib due to treatment-related adverse event (due to grade 3 portal vein thrombosis). One pt discontinued blinatumomab due to toxicity (due to persistent grade 2 tremor). No early deaths were observed. Conclusion: The chemotherapy-free combination of ponatinib and blinatumomab is a safe and effective regimen in both R/R Ph+ ALL and CML-LBP. High rates of deep molecular response were observed in R/R Ph+ ALL. However, CMR rates were relatively low in pts with CML-LBP, suggesting that alternative approaches should be considered in these pts. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yerong发布了新的文献求助10
刚刚
刚刚
锋芒不毕露完成签到,获得积分10
刚刚
小雷完成签到,获得积分10
1秒前
晴天yyyyy发布了新的文献求助10
2秒前
2秒前
脑洞疼的应助被碧蓝的飞丹采纳,获得10
2秒前
Smile完成签到,获得积分10
3秒前
3秒前
SA完成签到,获得积分10
4秒前
4秒前
weisu完成签到,获得积分10
5秒前
完美世界的应助被王木木采纳,获得10
6秒前
鸡鱼蚝发布了新的文献求助50
6秒前
游隼儿完成签到,获得积分10
7秒前
7秒前
学术雷锋发布了新的文献求助10
7秒前
小鱼爱吃肉的应助被活泼的筝采纳,获得10
7秒前
俊逸的鱼头完成签到,获得积分10
8秒前
xxjj发布了新的文献求助10
8秒前
hoax发布了新的文献求助20
8秒前
QG小趴菜发布了新的文献求助10
9秒前
Jeccy完成签到,获得积分10
9秒前
优美无极完成签到,获得积分10
9秒前
leilei完成签到 ,获得积分10
10秒前
Harriet完成签到,获得积分10
10秒前
10秒前
kaiyang发布了新的文献求助200
10秒前
oneovers发布了新的文献求助10
11秒前
11秒前
zhanglx66完成签到 ,获得积分10
11秒前
12秒前
breeze完成签到,获得积分10
12秒前
12秒前
英姑的应助被ccfyyds采纳,获得10
12秒前
星辰大海的应助被鸡鱼蚝采纳,获得10
13秒前
WUXIAOYONG完成签到,获得积分10
13秒前
DRJ发布了新的文献求助10
13秒前
方暂暗完成签到,获得积分10
13秒前
传奇3的应助被yly采纳,获得10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8161320
求助须知:如何正确求助?哪些是违规求助? 9556074
关于积分的说明 21732157
捐赠科研通 7751456
什么是DOI,文献DOI怎么找? 3427537
关于科研通互助平台的介绍 2552583
邀请新用户注册赠送积分活动 2471992